MDT

97.25

+1.88%↑

VEEV

300.62

+4.11%↑

A

139.72

-0.04%↓

HQY

90.34

-0.32%↓

PHR.US

23.41

+5.4%↑

MDT

97.25

+1.88%↑

VEEV

300.62

+4.11%↑

A

139.72

-0.04%↓

HQY

90.34

-0.32%↓

PHR.US

23.41

+5.4%↑

MDT

97.25

+1.88%↑

VEEV

300.62

+4.11%↑

A

139.72

-0.04%↓

HQY

90.34

-0.32%↓

PHR.US

23.41

+5.4%↑

MDT

97.25

+1.88%↑

VEEV

300.62

+4.11%↑

A

139.72

-0.04%↓

HQY

90.34

-0.32%↓

PHR.US

23.41

+5.4%↑

MDT

97.25

+1.88%↑

VEEV

300.62

+4.11%↑

A

139.72

-0.04%↓

HQY

90.34

-0.32%↓

PHR.US

23.41

+5.4%↑

Search

Amgen Inc

Open

SectorGezondheidszorg

300.2 0.93

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

294.88

Max

300.44

Belangrijke statistieken

By Trading Economics

Inkomsten

-298M

1.4B

Verkoop

1B

9.2B

K/W

Sectorgemiddelde

22.328

35.739

EPS

6.02

Dividendrendement

3.39

Winstmarge

15.621

Werknemers

28,000

EBITDA

2.4B

3.6B

Aanbevelingen

By TipRanks

Aanbevelingen

Buy

12 Maanden Prognose

+8.21% upside

Dividenden

By Dow Jones

Dividendrendement

Sectorgemiddelde

3.39%

3.08%

Volgende Winsten

4 nov 2025

Volgende dividenddatum

8 dec 2025

Volgende Ex Dividend datum

17 nov 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

-15B

147B

Vorige openingsprijs

299.27

Vorige sluitingsprijs

300.2

Nieuwssentiment

By Acuity

28%

72%

69 / 371 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Very Strong Bearish Evidence

Amgen Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

5 aug 2025, 20:51 UTC

Winsten

Amgen Posts Higher 2Q Profit, Revenue On Sales Growth Among Products

23 jun 2025, 19:24 UTC

Belangrijke Marktbewegers

Amgen Expands MariTide Development Plans After Weight-Loss Trial -- Update

23 jun 2025, 19:07 UTC

Belangrijke Marktbewegers

Amgen Expands MariTide Development Plans After Successful Weight-Loss Trial

1 mei 2025, 20:17 UTC

Winsten

Amgen 1Q Revenue Up 9% as Many Products Deliver Double-Digit Sales Growth

5 aug 2025, 20:01 UTC

Winsten

Amgen Sees FY Rev $35B-$36B >AMGN

5 aug 2025, 20:01 UTC

Winsten

Amgen Sees FY EPS $10.97-EPS $12.11 >AMGN

5 aug 2025, 20:01 UTC

Winsten

Amgen Sees FY Adj EPS $20.20-Adj EPS $21.30 >AMGN

5 aug 2025, 20:01 UTC

Winsten

Amgen 2Q Worldwide Prolia Sales $1.12B >AMGN

5 aug 2025, 20:01 UTC

Winsten

Amgen 2Q Worldwide XGEVA Sales $532M >AMGN

5 aug 2025, 20:01 UTC

Winsten

Amgen 2Q Net $1.43B >AMGN

5 aug 2025, 20:01 UTC

Winsten

Amgen 2Q Worldwide Enbrel Sales $604M >AMGN

5 aug 2025, 20:01 UTC

Winsten

Amgen 2Q Worldwide Neulasta Sales $82M >AMGN

5 aug 2025, 20:01 UTC

Winsten

Amgen 2Q Rev $9.2B >AMGN

5 aug 2025, 20:01 UTC

Winsten

Amgen 2Q Adj EPS $6.02 >AMGN

5 aug 2025, 20:01 UTC

Winsten

Amgen 2Q EPS $2.65 >AMGN

28 mei 2025, 18:09 UTC

Winsten

Heart Disease Could Be a Goner When These New -2-

28 mei 2025, 18:09 UTC

Winsten

Heart Disease Could Be a Goner When These New Drugs Arrive -- Barrons.com

19 mei 2025, 16:13 UTC

Acquisities, Fusies, Overnames

Regeneron Is Buying 23andMe. The Deal Is a Head Scratcher. -- Barrons.com

1 mei 2025, 20:01 UTC

Winsten

Amgen: FY25 Share Repurchases Not to Exceed $500M

1 mei 2025, 20:01 UTC

Winsten

Amgen: Guidance Includes Estimated Impact of Implemented Tariffs>AMGN

1 mei 2025, 20:01 UTC

Winsten

Amgen Sees FY25 Capital Expenditures About $2.3B

1 mei 2025, 20:01 UTC

Winsten

Amgen: Guidance Doesn't Account for Any Tariffs That Could Be Implemented in Future, Including Sector-specific Tariffs

1 mei 2025, 20:01 UTC

Winsten

Amgen 1Q Repatha Sales $656M >AMGN

1 mei 2025, 20:01 UTC

Winsten

Amgen 1Q EVENITY Sales $442M >AMGN

1 mei 2025, 20:01 UTC

Winsten

Amgen 1Q Worldwide Neulasta Sales $129M >AMGN

1 mei 2025, 20:01 UTC

Winsten

Amgen Sees FY25 Adj EPS $20-Adj EPS $21.20 >AMGN

1 mei 2025, 20:01 UTC

Winsten

Amgen 1Q Net $1.73B >AMGN

1 mei 2025, 20:01 UTC

Winsten

Amgen Sees FY25 EPS $12.21-EPS $13.46 >AMGN

1 mei 2025, 20:01 UTC

Winsten

Amgen 1Q Adj EPS $4.90 >AMGN

1 mei 2025, 20:01 UTC

Winsten

Amgen Sees FY25 Rev $34.3B-$35.7B >AMGN

Peer Vergelijking

Prijswijziging

Amgen Inc Prognose

Koersdoel

By TipRanks

8.21% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 323 USD  8.21%

Hoogste 405 USD

Laagste 272 USD

Gebaseerd op 21 Wall Street-analisten die 12-maands prijsdoelen bieden voor Amgen Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

21 ratings

9

Buy

11

Hold

1

Sell

Technische score

By Trading Central

270.44 / 276.44Steun & Weerstand

Korte Termijn

Very Strong Bearish Evidence

Gemiddeld Termijn

Strong Bearish Evidence

Lange Termijn

Bearish Evidence

Sentiment

By Acuity

69 / 371 Rangschikking in Gezondheidszorg

Nieuwssentiment

Bullish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Onder gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Amgen Inc

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.
help-icon Live chat